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Objective: The worldwide prevalence of obesity has increased to 10% in men and 15% in women and is associated with severe comorbidities
such as diabetes, cancer, and cardiovascular disease. Animal models of obesity are central to experimental studies of disease mechanisms and
therapeutic strategies. Diet-induced obesity (DIO) models in rodents have provided important insights into the pathophysiology of obesity and, in
most instances, are the ﬁrst in line for exploratory pharmacology studies. To deepen the relevance towards translation to human patients, we
established a corresponding DIO model in Göttingen minipigs (GM).
Methods: Young adult female ovariectomized GM were fed a high-fat/high-energy diet for a period of 70 weeks. The ration was calculated to
meet the requirements and maintain body weight (BW) of lean adult minipigs (L-GM group) or increased stepwise to achieve an obese state (DIO-
GM group). Body composition, blood parameters and intravenous glucose tolerance were determined at regular intervals. A pilot chronic treatment
trial with a GLP1 receptor agonist was conducted in DIO-GM. At the end of the study, the animals were necropsied and a biobank of selected
tissues was established.
Results: DIO-GM developed severe subcutaneous and visceral adiposity (body fat >50% of body mass vs. 22% in L-GM), increased plasma
cholesterol, triglyceride, and free fatty acid levels, insulin resistance (HOMA-IR>5 vs. 2 in L-GM), impaired glucose tolerance and increased heart
rate when resting and active. However, fasting glucose concentrations stayed within normal range throughout the study. Treatment with a long-
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relative to observations in other DIO animal models. Extensive adipose tissue inﬂammation and adipocyte necrosis was observed in visceral, but
not subcutaneous, adipose tissue of DIO-GM.
Conclusions: The Munich DIO-GM model resembles hallmarks of the human metabolic syndrome with extensive adipose tissue inﬂammation
and adipocyte necrosis reported for the ﬁrst time. DIO-GM may be used for evaluating novel treatments of obesity and associated comorbidities.
They may help to identify triggers and mechanisms of fat tissue inﬂammation and mechanisms preventing complete metabolic decompensation
despite morbid obesity.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The prevalence of obesity is persistently increasing worldwide, and the
magnitude has nearly doubled in more than 70 countries since 1980.
In 2015, approximately 604 million adults were considered obese [1].
Visceral obesity is associated with numerous adverse metabolic ef-
fects, including insulin resistance [2], dyslipidemia [3], and hyper-
tension [4]. Obese individuals are susceptible to co-morbidities such as
type 2 diabetes mellitus [5], nonalcoholic fatty liver disease (NAFLD)
and steatohepatitis [6], asthma [7], certain cancers [8], and cardio-
vascular [9] and neurodegenerative diseases [10]. The clustered
hallmarks of the metabolic syndrome (hyperglycemia, hypercholes-
terolemia, hypertension and obesity) are major risk factors for car-
diovascular disease [11].
Persistent positive energy balance leads to hypersecretion of insulin
and catecholamines as well as fat accumulation. It occurs mainly in
classical subcutaneous and visceral fat depots but also at multiple
other sites like lung, blood vessel wall, epicardium, kidney and bone
marrow [12]. While visceral fat depots are closely linked to metabolic
disease, subcutaneous fat depots are protective [13].
In adipocytes, excessive fat storage initiates an inﬂammatory stress
response characterized by the secretion of a large variety of chemo-
kines (reviewed in [14]). Although the initial inﬂammatory response
seems to be necessary for acute, physiological fat tissue expansion
[15], chronic and centralized, low-grade inﬂammation triggers insulin
resistance. It is accompanied by adipocyte death, abnormal fat tissue
remodeling and ﬁbrosis in rodents [16] and humans [17].
To date the metabolic consequences of excessive fat storage are well
understood, but the actual triggers and underlying mechanisms of
adipose tissue inﬂammation are uncertain [18]. A deeper understanding
of inﬂammatory triggers and mechanisms may uncover novel thera-
peutic targets for treatment of obesity and associated comorbidities.
In this respect, animal models that manifest critical disease aspects of
human obesity and co-morbidities are important for increasing our
knowledge of pathological processes and assessment of drug candi-
dates for translation to human subjects. Diet-induced obese (DIO)
rodent models are most often the ﬁrst-line option for pharmacological
evaluation, but their predictive value for drug efﬁcacy and safety in
humans is limited [19,20]. Given the strong similarity of human
anatomy and physiology to pigs, they can serve as a model bridging
the gap between mouse and man [20,21].
Therefore, we have established a DIO model in Göttingen minipigs (GM)
to complement a well-characterized DIO mouse model [22,23]. Munich
DIO-GM showed phenotypic signatures representative of the metabolic
syndrome, as well as extensive fat tissue inﬂammation. A biobank of
selected tissues from DIO-GM and lean controls (L-GM) was estab-
lished for future molecular proﬁling studies aimed at the discovery of
biomarker candidates and therapeutic targets.MOLECULAR METABOLISM 16 (2018) 180e190  2018 The Authors. Published by Elsevier GmbH. This is an open a
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2.1. Animals and study outline
Twenty-six female Göttingen minipigs (GM), 11e13 months of age,
were purchased from Ellegaard Göttingen Minipigs A/S, Dalmose,
Denmark. Pigs were group-housed until central venous catheters were
placed, with straw litter and ad libitum access to water. All experi-
ments were performed according to the German Animal Welfare Act
with permission from the responsible authority (Government of Upper
Bavaria), following the ARRIVE guidelines and Directive 2010/63/EU.
Following an acclimatization period of six weeks, pigs were ovariec-
tomized (see Supplemental methods). The study outline is shown in
Figure 1A.
2.2. Diet and feeding regimen
The composition of the experimental diet (high-fat/high-energy;
HFHE) is outlined in Suppl. Table 1. The animals were randomized
into two experimental groups according to their body fat mass (ﬁrst
DXA measurement) in the ﬁrst and body weight in the second order:
lean and obese. Both groups were fed a restricted ration of the same
diet once daily. For the lean group (L-GM), the ration was calculated
to meet the energy and nutrient requirements of adult pigs [24]. For
the obese group (DIO-GM), the daily ration was increased stepwise
to achieve a weekly BW gain of 1.0e1.5 kg up to 80 kg BW and
0.5e1.0 kg from 80 to 100 kg BW. From feeding week (FW) 55
onwards, DIO-GM were offered food ad libitum for 1 h in the morning
and 1 h in the afternoon (see pilot treatment trial below). Pigs were
individually fed throughout the study period and the daily ration was
measured for each pig.
2.3. Diet digestibility
The apparent digestibility (aD) of nutrients was determined at FW 20
(DI) and 70 (DII). Titanium oxide (0.1% of dry matter) was added to the
food as marker, and feces were collected from each individually
housed minipig for a 5-day period. Subsequently, food and feces were
freeze-dried, grinded, and mixed thoroughly. Crude nutrients were
determined using the Weende method (VDLUFA 2012) and gross en-
ergy (GE) using an adiabatic bomb calorimeter. For mineral analysis,
wet digestion of feed and fecal samples was performed in a microwave
digestion unit (MLS Ethos 1600). Calcium was determined by ﬂame
emission spectrometry (EFOX 5053, Eppendorf AG, Hamburg, Ger-
many) and phosphorus photometrically with ammonium molybdate
and ammonium vanadate in HNO3 (GENESYS 10 UV, Thermo Spec-
tronic, Rochester, NY, USA). Using the aD of GE from the balancing
trials based on the following equation, digestible energy (DE) intake
was calculated:
aD [%] ¼ 100  [% marker diet/% marker feces  % nutrient feces/
% nutrient food] * 100.ccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 181
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Body weight was determined two (up to FW 54) or three times (treat-
ment trial) per week using an F. Star 125 large animal scale (Meier-
Brakenberg). Whole body composition was evaluated by dual-energy X-
ray absorptiometry (GE Lunar iDXA scanner; GE Healthcare GmbH,
Solingen, DE) prior to HFHE feeding (0) as well as in FW 18, 30 and 54
as described in [25]. In addition, magnetic resonance tomography
(MRT; Magnetom Open Scanner, 0.2 T, Siemens) was performed in FW
30 using a T1-weighted sequence as described in [26] with a slice
thickness ¼ 15 mm, ﬁeld of view ¼ 461 mm  461 mm, TR (time of
repetition) ¼ 380 ms, and TE (time between echoes) ¼ 15 ms.
2.5. Blood parameters
Blood samples were taken after an overnight fasting period of 18e20 h
prior to the start of HFHE feeding (0) and in FW 18, 30, and 54. Blood
was collected into EDTA-coated and non-coated tubes (Monovette
blood collection system, Sarstedt). EDTA-plasma tubes were immedi-
ately stored on ice, while serum tubes were kept at room temperature
for 20 min to allow complete clotting. Then plasma/serum was sepa-
rated by centrifugation (1,500 g, 4 C, 15 min), aliquoted and stored
at 80 C. Plasma insulin levels were determined using a species-
speciﬁc RIA (Merck Millipore). Clinical-chemical parameters were
determined from EDTA-plasma or serum (Suppl. Table 2) using an
AU480 autoanalyzer (BeckmaneCoulter) and adapted reagent kits from
BeckmaneCoulter or Sentinel. Amylase and lipase were determined
using an ILab 650 analyzer (Werfen GmbH) and respective reagent kits.
2.6. Intravenous glucose tolerance test (IVGTT)
For stress-free, frequent blood sampling in unrestrained animals,
central venous catheters were placed into a marginal ear vein
(Suppl. Methods). IVGTTs were performed in FW 29 and 54 as previ-
ously described [27].
2.7. Heart rate
Non-invasive heart rate measurement was performed in FW 59 and 69
using a Zephyr BioHarness 3.0 system (Cosmed) at rest (lying animal)
and during a relaxed walk of 1 min duration. Animal behavior was
monitored during the entire recording period.
2.8. Pilot treatment trial
Starting at feeding week 60, a pilot pharmacology trial was performed
using a long acting GLP1 receptor (GLP1R) agonist in chronic treatment.
Eight obese GM (96.4 3.1 kg) were randomized according to body fat
mass determined by DXA (FW 54) and body weight to placebo admin-
istration (0.9% NaCl) or treatment with a GLP1R agonist (acylated GLP1,
i.e. GLP1 [Aib2 E16 Cex K40-C16 acyl] [28]). Two weeks prior to treatment
start, GM received ad libitum food for 1 h in the morning (08:00e09:00)
and 1 h in the afternoon (03:00e04:00). Compound/placebo was
subcutaneously injected once daily (between 08:00 and 08:30) into the
popliteal crease for a total period of 29 days, twenty days with a dosage
of 0.1 mg/kg BW and nine days with 0.2 mg/kg BW. During the treatment
period, food intake was recorded once daily, and body weight was
recorded three times per week. Animals were continuously monitored
for the occurrence of possible gastrointestinal side effects.
2.9. Pathological examination and establishment of a biobank
Following a wash-out period of four weeks for trial participants, all
animals were necropsied. Pigs were anesthetized by intramuscular
injection of ketamine (Ursotamin, Serumwerke Bernburg, 20 mg/kg
BW) and azaperone (Stresnil, Elanco, 2 mg/kg BW) followed by
intravenous application of ketamine and xylazine (Xylazin 2%,182 MOLECULAR METABOLISM 16 (2018) 180e190  2018 The Authors. Published by Elsevier GmbH.Serumwerk Bernburg). Blood samples were taken by cardio puncture.
Animals were then euthanized under anesthesia by intravenous in-
jection of Pentobarbital (Release, WDT, at least 450 mg/10 kg BW)
and immediately subjected to necropsy. Body weight and the weights,
dimensions, and densities of internal organs and different deﬁned
adipose tissue depots (refer to Suppl. Table 5 and Suppl. Figure 4)
were determined, according to standardized tissue sampling guide-
lines as described previously [29,30]. Samples designated for mo-
lecular proﬁling were shock frozen to80 C within a period of 20 min
after death of the animal. Tissue samples for histopathological ana-
lyses were ﬁxed in neutrally buffered 4% formaldehyde solution and
processed for parafﬁn-histology or cryo-histology according to stan-
dard protocols [29]. Transversal sections of formalin-ﬁxed, parafﬁn-
embedded tissue samples of terminal abdominal aorta and of cardiac
coronary arteries were stained with HE, giemsa, picrosirius red, and
Masson’s trichrome. For demonstration of lymph-vessels in parafﬁn
sections of lung tissue, the lymphatic marker protein LYVE1 (lymphatic
vessel endothelial hyaluronic acid receptor 1) was detected by
immunohistochemistry, using a polyclonal rabbit anti-LYVE1 IgG
antibody (1:100, ab 33682, Abcam, UK), a horse-radish peroxidase-
coupled goat anti-rabbit IgG secondary antibody (1:100, P0448,
Dako, Denmark), diaminobenzidine as ﬁnal chromogen, and
hemalum as nuclear counterstain. A biobank collection of samples of
>20 different organs, tissues and body ﬂuids was established [29],
providing adequately processed specimen for a broad spectrum of
subsequent analysis methods, including molecular analyses of RNA,
proteins, and metabolites, microbiomic analyses of intestinal contents,
as well as qualitative and quantitative morphological analyses on the
level of light- and electron microscopy (Supplementary Table 7).
2.10. Determination of adipose tissue necrosis volumes
The excised retroperitoneal adipose tissue of the abdominal wall
(rpAW) was cut completely into parallel stripes of tissue approxi-
mately two centimeter thickness. The tissue stripes were placed on
the same cut-surfaces and photographed vertically from above,
together with a ruler. Digital images of the photographs were
superimposed with test grids of equally spaced test points. The
volume density of necrotic/inﬂamed adipose tissue in the rpAW-
adipose tissue (VV(Necrosis/rpAW)) was determined by point counting
[31,32] as the quotient of the number of points hitting section areas of
inﬂammation/necrosis within the rpAW-adipose tissue and the
number of points hitting the rpAW-adipose tissue. Per case, 612 58
points were counted. The total necrosis volume in the rpAW-adipose
tissue (V(Necrosis, rpAW)) was calculated by multiplication of VV(Necrosis/
rpAW) with the total volume of the rpAW-adipose tissue (V(rpAW)). The
latter was calculated from the weight of the entire rpAW-fat depot and
its tissue density [29].
2.11. Statistics
All data are presented as means  SEM. For statistical analysis,
longitudinal data for body weight, food intake, glucose and insulin
levels during IVGTT were evaluated by ANOVA (Linear Mixed Models;
SAS 8.2) taking the ﬁxed effects of Group (obese vs. lean), Time
(relative to glucose administration/feeding/treatment duration), and the
interaction Group*Time into account. Data of body composition (DXA),
clinical-chemical analyses, fasting glucose/insulin levels, HOMA-IR,
organ weights/volumes and food digestibility were evaluated by
ANOVA (General Linear Models; SAS 8.2) taking the ﬁxed effects of
Group, Time (¼ feeding duration) if applicable, and the interaction
Group*Time into account. AUC insulin/glucose was calculated using
GraphPad Prism software (version 5.02). AUCs and all remainingThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Study outline, body weight development, and body composition of Göttingen minipigs fed a HFHE-diet for 70 weeks. (A) Study outline: age of minipigs from the
lean (L, n ¼ 5) and obese group (O, n ¼ 21) at the study start: 13 months, FBS: fasting blood sampling, IVGTT: intravenous glucose tolerance test, HR: heart rate, TT: treatment
trial, DXA: dual-energy X-ray absorptiometry, MRT: magnetic resonance tomography. (B) Body weight gain of minipigs from the lean and obese group. (CeF) Body composition
evaluated by DXA prior to HFHE-diet feeding (0) and at feeding week 18, 30 and 54, (C) Relative fat mass (%), (D) Absolute lean mass (kg), (E) Absolute bone mineral content
(BMC, kg), (F) Bone mineral density (g/cm2). (G, H) Representative MRT images of a lean (G) and an obese (H) minipig at the level of the kidneys showing subcutaneous and
visceral obesity. Data are means  SEM; *: p<0.05, **: p<0.01, ***: p<0.001. Signiﬁcant differences within the groups are indicated by different letters, differences between lean
and obese animals at the respective time point are indicated by asterisks.
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test using GraphPad Prism software. If not indicated otherwise, p
values less than 0.05 were considered signiﬁcant.
3. RESULTS
3.1. HFHE-overfed Göttingen minipigs develop severe general
obesity
Animals in the lean group (L-GM) received 3.1  0.4 MJ DE/day
(a0.2 0.03 MJ DE/kg BW0.75) throughout the trial to maintain a lean
body mass. Minipigs of the obese group (DIO-GM) consumed
10.8  1.6 MJ DE/day (a0.50  0.07 MJ DE/kg BW0.75) during the
ﬁrst (DI) and 51.1  20.8 MJ DE/day (a 1.57  0.55 MJ DE/kg
BW0.75) during the second (DII) diet digestibility test. The apparent di-
gestibility (aD) of crude protein and nitrogen-free extracts (NfE)
increased signiﬁcantly with age (Suppl. Table 2; p< 0.03). The aD of all
crude nutrients except crude fat (dry matter, crude protein, crude ﬁber,
and NfE) was moderately but signiﬁcantly higher in DIO-GM compared
with L-GM (pairwise multiple comparison procedures). However, the aD
of gross energy (GE) was not signiﬁcantly different. The protein used in
the diet was highly digestible throughout the trial (aD > 90%).
Prior to HFHE feeding, lean and obese minipigs were not signiﬁcantly
different in body weight (Figure 1B). After HFHE feeding, animals from
the obese group constantly increased in body weight. At FW 18, 30,
and 54, the body weights of DIO-GM were increased by 39%, 87%,
and 120%, respectively, compared to age-matched L-GM. At the end
of the study period (FW 70), the body weight of DIO-GM was increased
by 136% relative to the age-matched L-GM (103.3  3.7 vs.
43.6  1.8 kg, p < 0.0001, Figure 1B).
Whole body DXA scans were performed prior to HFHE feeding as well
as in FW 18, 30, and 54. While no signiﬁcant differences were
initially detected between the lean and obese groups, excessive
HFHE feeding resulted in a constant and signiﬁcant increase of total
tissue (TT, Suppl. Figure 1A), fat mass (Figure 1C), lean mass
(Figure 1D) and BMC (Figure 1E) in DIO-GM, while body composition
of L-GM was maintained from week 18 onwards (Figure 1 &
Suppl. Figure 1). Body composition of DIO-GM shifted towards fat
mass (53.8% of TT at FW 54 in obese animals vs. 22.2% in lean
animals; Figure 1C, Suppl. Figure 1B). MRT analyses at FW 30
revealed severe subcutaneous and visceral adiposity in DIO-GM
(Figure 1G,H).
3.2. Obese Göttingen minipigs show an altered lipid proﬁle
Prior to HFHE diet feeding, measures of clinical chemistry were
comparable between the L-GM and DIO-GM minipigs (Suppl. Table 3).
After 18 weeks of restricted HFHE feeding, L-GM showed signiﬁcantly
increased plasma total cholesterol and bilirubin concentrations, while
iron concentration and alkaline phosphatase activity were decreased
compared to the pre-feeding period (Figure 2A, Suppl. Table 3). DIO-
GM showed pronounced alterations in lipid metabolism. Total
cholesterol and triglyceride levels were signiﬁcantly elevated at FW 18
and 30, but unaltered at FW 54 (Figure 2A,B). Plasma NEFA levels of
DIO-GM were signiﬁcantly increased at FW 54 (Figure 2C). Plasma
levels of alanine-aminotransferase (ALT) were signiﬁcantly reduced in
DIO-GM vs. L-GM at FW 18, 30, and 54, while levels of aspartate-
aminotransferase (AST) trended lower. Plasma levels of gamma-
glutamyl transferase (GGT) were also signiﬁcantly reduced at FW 54
(Suppl. Table 3). In addition, reduced plasma concentrations of total
bilirubin and creatinine were observed in DIO-GM at FW 18 and 30. In
contrast, plasma urea levels of DIO-GM were elevated at FW 18 and 30
(Suppl. Table 3).184 MOLECULAR METABOLISM 16 (2018) 180e190  2018 The Authors. Published by Elsevier GmbH.3.3. Obese Göttingen minipigs reveal substantial hyperinsulinemia,
insulin resistance and reduced glucose tolerance
DIO-GM had impaired glucose tolerance at FW 30 and 54 (13% and
39% higher AUC glucose than in L-GM; Figure 2D,E). Accordingly,
glucose elimination rate was signiﬁcantly decelerated at both time-
points (Figure 2D,E). Fasting plasma glucose was signiﬁcantly
increased at FW 30 (Figure 2F), but remained within the reference
range throughout the whole study period. Glucose-stimulated insulin
secretion was markedly increased (79% and 175% increased AUC
insulin compared to L-GM at FW 30 and 54, respectively; Figure 2G,H),
resulting in signiﬁcantly increased insulin:glucose ratios (Figure 2J,K).
In addition, fasting insulin levels (Figure 2I) and HOMA-IR (Figure 2L)
were signiﬁcantly increased in DIO-GM at FW 30 and 54.
3.4. Increased heart rate in obese Göttingen minipigs at rest and
during activity
Resting heart rate (beats per minute; bpm) was signiﬁcantly elevated in
DIO-GM compared to L-GM in FW 60 (96.9 3.6 vs. 58.5  4.8 bpm,
p ¼ 0.0003) and FW 69 (99.0  4.2 vs. 66.9  5.8 bpm, p ¼ 0.001)
(Suppl. Figure 2). After 1 min of relaxed walking, the heart rates of DIO-
GM and L-GM increased to 147.7  9.4 and 91.9  4.4 bpm
(p ¼ 0.007), respectively, with peak levels of 175  10.9 bpm and
107  5.1 bpm in the two groups (Suppl. Figure 2).
3.5. DIO Göttingen minipigs show reduced food intake and weight
reduction during short-term treatment with a GLP1R agonist
To examine the translatability of the DIO-GM model in regard to a phar-
macological response, DIO-GM were treated for four weeks with a long-
acting GLP1R agonist in an up-titration dosing regimen. The up-titration
design (0.1 mg/kg BW for 20 days and 0.2 mg/kg BW for nine days)
was employed to more mimic the dosing schedule in humans with lir-
aglutide [33]. Treatmentwith the GLP1R agonist reduced daily food intake
through the ﬁrst two days relative to vehicle controls (Suppl. Figure 3A).
Thereafter, daily food intake steadily increased and reached steady-state
at treatment day 10 butwas still signiﬁcantly lower than in vehicle-treated
DIO-GM (Suppl. Figure 3A). The dose increase to 0.2 mg/kg BW caused a
more pronounced reduction in daily food intake compared to the initial
dose. After treatment termination, daily food intake was normalized
(Suppl. Figure 3A). By the end of this four-week study, DIO-GM treated
with the GLP-1R agonist had a mean loss in BW of 1.5% from baseline
while vehicle-treated DIO-GM had a mean BW gain of 4.6% (p ¼ 0.09,
Suppl. Figure 3B) from baseline. GLP1R agonist treatment did not cause
signiﬁcant changes in hematological and clinical-chemical parameters as
determined at the end of the treatment trial (Suppl. Table 4).
3.6. Establishment of a biobank and pathomorphological
alterations of adipose tissue
A biobank collection of samples of >20 different organs, tissues, and
body ﬂuids was established (Figure 3A), providing adequately pro-
cessed specimen for a broad spectrum of subsequent analyses. This
includes molecular analyses of RNA, proteins and metabolites,
microbiomic analyses of intestinal contents, as well as qualitative and
quantitative morphological study by light- and electron microscopy
(details in Supplementary Table 7). DIO-GM displayed morbid obesity
with massively enlarged subcutaneous and visceral fat tissue depots
(Figure 3B,C). The proportion of subcutaneous and visceral fat in total
fat was unaltered in DIO-GM compared to L-GM (data not shown).
Apart from general obesity, DIO-GM consistently displayed a spectrum
of morphological alterations. The most striking was the development of
multifocal, severe adipose tissue inﬂammation and adipocyte necrosis
in visceral abdominal adipose tissue depots (Figure 3DeL).This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Fat metabolism and glucose control during IVGTT and insulin sensitivity in Göttingen minipigs fed a HFHE-diet for 70 weeks. Clinical-chemical analyses from
plasma samples of lean (L) and obese (O) minipigs prior to HFHE-diet feeding (0) and at feeding week 18, 30 and 54; (A) Total cholesterol, (B) triglycerides, (C) non-esteriﬁed fatty
acids (NEFA). (D e L) IVGTT from feeding week 30 (D, G, J) and 54 (E, H, K): Plasma glucose levels; the insert shows the net glucose elimination rate after glucose injection as
calculated as the slope for the interval 1e30 min after glucose injection of the logarithmic transformation of the individual plasma glucose values (D, E); Plasma insulin levels (G,
H); Insulin to glucose ratio (J, K); Fasting glucose (F) and insulin (I) levels; HOMA-IR (L). Data are means  SEM; *: p<0.05, **: p<0.01, ***: p<0.001.The volume density (Vv(necrot. fat/total rpAW)) and total volume
(V(necrot. fat, total rpAW)) of necrotic fat tissue within the most affected
abdominal retroperitoneal compartment was 8.7  1.9% (range: 2e
25%) and 178.5  38.8 cm3 in DIO-GM (Figure 3M). One animal
within the DIO-GM group did not exhibit macroscopically identiﬁable
areas of necrosis within the visceral adipose tissue. In histological
sections, the proﬁles of adipocytes in rpAW of DIO-GM consistentlyMOLECULAR METABOLISM 16 (2018) 180e190  2018 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comappeared conspicuously larger than those of L-GM, as well as
compared to the section proﬁles of subcutaneous adipocytes of both
DIO-GM and L-GM (Figure 4AeF). Histopathological examination of
samples from macroscopically altered and unaltered rpAW of DIO-
GM revealed a spectrum of partially merging morphological ﬁnd-
ings, ranging from largely physiological (yet hypertrophic) fat cells,
foci of acute single fat cell necrosis with moderate interstitialccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 185
Figure 3: Biobank, macroscopic characteristics and quantitative-stereological
analyses of fat tissue necroses in 3-year-old, ovariectomized Göttingen mini-
pigs fed a HFHE-diet for 70 weeks. (A): Body ﬂuids and tissues collected from lean
(L) and obese (O) minipigs for the establishment of a biobank, see also Supplementary
Table 7 for more detailed information; (B, C): Mass (B) and total volumes (C) of
different fat tissue compartments, TAT: total adipose tissue, SAT: subcutaneous adi-
pose tissue, VAT: visceral adipose tissue; (DeJ): Within the visceral adipose tissue, foci
of fat tissue necrosis were most frequently observed in the following regions: (D) the
retroperitoneal adipose tissue of the lateral abdominal wall (rpAW); view into the
ventrally opened abdominal cavity. Note the white, dense areas of adipose tissue
inﬂammation and necrosis in the retroperitoneal adipose tissue of the abdominal wall
(arrow) and the fat tissue necrosis at the distal end of the splenic lobe of the pancreas
lined by a hyperemic rim (line), bar ¼ 6 cm; (E,F) the peri-pancreatic adipose tissue;
unaltered morphology of the distal end of the pancreas’ splenic lobe in a lean, need-
based-fed minipig, bar ¼ 3.5 cm (E) and detail enlargement of the peri-pancreatic fat
tissue necrosis shown in (F), bar ¼ 3.5 cm; (G) the omental adipose tissue at the
splenic hilus (arrow), bar ¼ 2.5 cm and (H) the omental adipose tissue at the greater
gastric curvature, bar ¼ 7 cm; (I) the peri-renal retroperitoneal adipose tissue at the
lateral abdominal wall (bar ¼ 4 cm), and (J) less frequently in the jejunal and colonic
Brief Communication
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necrosis, and severe chronic inﬂammatory cell inﬁltration of mac-
rophages, multinucleate giant cells, and fewer neutrophils, lym-
phocytes, and plasma cells, accompanied by variable interstitial
ﬁbrosis, multifocal mineralization, and occasionally focal purulent
liquefaction (Figure 4AeF). These alterations were particularly pro-
nounced in the intra- and peripancreatic adipose tissue
(Figure 4G,H). In contrast, adipose tissue inﬂammation and adipocyte
necrosis was not observed in subcutaneous tissue of DIO-GM.
Importantly, the subcutaneous and visceral fat tissue of L-GM did
not show histopathological signs of inﬂammation or cell death.
In the liver of DIO-GM, multifocal hepatic foam-cell granulomas (ac-
cumulations of lipid-loaded macrophages, Figure 4I) were sporadically
observed, whereas hepatocytic fat accumulation was only occasionally
present while in skeletal muscles and the myocardium (Figure 4J)
moderate interstitial lipidosis was observed.
In the terminal abdominal aorta and in cardiac coronary arteries of DIO-
GM and L-GM, small, fatty, streak-like alterations were sporadically
present while occlusive atherosclerotic lesions were not observed in
any case (Suppl. Figure 5).
Throughout the observational period, eight minipigs had to be eutha-
nized prior to the end of the study due to a severely decreased general
condition associated with reduced food intake and dyspnea. Post-
mortem histopathological analyses showed substantial diffuse pul-
monary lymphangiectasis and lymphatic lipidosis, as captured by IHC-
detection of the lymphatic marker LYVE1 (lymphatic vessel endothelial
hyaluronic acid receptor 1, Figure 4K, L).
4. DISCUSSION
To establish a large animal model for obesity research, we induced
obesity by excessive feeding of a high-fat/high-energy diet (HFHE) in
Göttingen minipigs, since this genetic background is frequently used in
pharmaceutical research. Due to its relatively small size, compound
testing in adult, obese animals is facilitated compared to domestic pig
breeds considering handling and costs. A special HFHE diet was
designed based on the fat, carbohydrate and protein sources and
content used for a well-characterized DIO mouse model [22,23]. This
enables comparative obesity studies between the two species.
Munich DIO-GM displayed crucial hallmarks of the metabolic syn-
drome, such as subcutaneous and visceral obesity, dyslipidemia,
impaired glucose tolerance, fasting hyperinsulinemia and insulin
resistance. The degree of obesity (44% and 54% mean total fat mass/
body weight at FW 30 and 54 respectively) is in the same range as in
women with advanced (>40% body fat) or morbid (>50% body fat)
obesity [34]. Accordingly, the increased body weight of DIO-GM
resulted preferentially from accumulation of fat mass (11-fold higher
than in L-GM), whereas lean mass was only 1.6-fold increased,
underlining the propensity of minipigs for obesity [35]. With increasing
body weight and obesity DIO-GM showed a stepwise decrease inmesentery, bar ¼ 9 cm; (K, L): Detail enlargement of transverse sections of necrotic
foci in the retroperitoneal fat tissue of the abdominal wall: areas of adipose tissue
inﬂammation and necrosis in the visceral abdominal adipose tissue present as focally
extensive, partially conﬂuent, nodular, ﬁrm, white to yellow, dry, chalky, granular, and
occasionally centrally liqueﬁed foci of 0.5e20 cm in diameter, with ill-deﬁned, irreg-
ularly shaped and hyperemic borders, Bars ¼ 1 cm (K) and ¼ 1.5 cm (L); (M):
Quantitative stereological analyses of necrotic/inﬂamed fat tissue areas in the retro-
peritoneal adipose tissue of the abdominal wall (rpAW), the mostly affected visceral fat
tissue compartment; Total volume (V(Necrosis, rpAW)) of fat tissue necrosis in retroperi-
toneal adipose tissue of the abdominal wall (rpAW). Data are means  SEM.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: Histopathological ﬁndings in 3-year-old, ovariectomized Göttingen
minipigs fed a HFHE-diet for 70 weeks. HE-stained parafﬁn-sections (AeK); Oil-red
stained cryo-sections (L and inset to I). AeD: Histomorphology of unaltered subcu-
taneous adipose tissue of the back (scB A, B) and of retroperitoneal adipose tissue of
the lateral abdominal wall (rpAW, C, D) of lean, need-based HFHE-fed control pigs and
obese HFHE-fed pigs without evident inﬂammatory or necrotic alterations. Note the
drastically increased section proﬁle areas of retroperitoneal adipocytes in obese pigs
(D). Bars ¼ 100 mm. E, F: Necrotic and inﬂammatory alterations in the retroperitoneal
adipose tissue of obese HFHED-fed pigs. Bars ¼ 100 mm. E: Moderate interstitial,
perivascular lymphocytic inﬁltration, edema, hypertrophy of vascular walls and capillary
endothelia, focal hemorrhage, and mild interstitial ﬁbrosis. F: Extensive fat cell necrosis
with saponiﬁcation, cholesterol-crystal formation, and severe granulomatous inﬂam-
mation (macrophages and numerous multinucleate giant cells). GeL: Visceral organ
lesions in obese HFHED-fed pigs. G, H: Pancreas. G: Severe peri-pancreatic necrosis of
fat (right side). Bar ¼ 1 mm. H: Detail enlargement, illustrating the loss of acinar
exocrine pancreatic parenchyma with (regenerative) proliferation of pancreatic duct
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resulting change in energy expenditure could be an additional trigger of
excessive obesity and associated metabolic alterations.
Obese minipigs revealed a similar increase in the total volumes of sub-
cutaneous (5.3-fold) and visceral fat tissue depots (4.9-fold), supporting
the notion that fat distribution to visceral and subcutaneous depots is a
heritable trait not altered by excessiveweight gain [36,37]. Fat distribution
to subcutaneous (80%) and visceral fat depots (20%) in L-GM and DIO-
GM was comparable to lean [38] and obese humans [39]. In contrast,
the proportion of visceral fat mass is substantially larger in lean (>40% of
total fat mass) [40] and DIO mice (up to 70% of total fat mass) [41,42],
which could be the reason for species-related physiological differences.
Diet digestibility tests conﬁrmed a supply of all required nutrients in
balanced amounts for lean and obese animals. The low apparent di-
gestibility (aD) of fat was probably due to the fact that palm fat (stearin)
was used in a reﬁned form. The low aD of this major nutrient fraction
also resulted in a reduced aD of dry matter and total energy. The
moderate but signiﬁcant increase of nutrient digestibility between the
ﬁrst and second balancing trial might be related to maturation of the
animal’s digestive physiology combined with an effect of habituation.
Obesity resulted in changes of multiple plasma metabolites. Compared
with L-GM, plasma levels of total cholesterol and triglycerides were
signiﬁcantly increased in DIO-GM at FW 18 and 30, but unaltered at FW
54. This is most likely due to the lower daily energy intake (8 MJ ME) at
FW 54 compared to 14 and 22 MJ ME at FW 18 and 30, respectively. In
general, the total cholesterol pool is dependent on dietary intake, de
novo synthesis, absorption efﬁciency, and excretion [43]. In contrast,
fasting NEFA concentrations of DIO-GM were exclusively elevated in
FW 54. This may be related to progressive deterioration of insulin
sensitivity, as insulin is a potent inhibitor of lipolysis [44].
Plasma urea concentrations of DIO-GM were signiﬁcantly increased in
FW 18 and 30, but not different from L-GM at FW 54. This is most likely
linked to the amount of dietary protein intake [45]. In addition, urea is a
side-product of gluconeogenesis [46] that is physiologically inhibited
by insulin. Progressive insulin resistance in DIO-GM may thus
contribute to a higher urea production.
Interestingly, DIO-GM revealed signiﬁcantly lower plasma creatinine
levels than L-GM throughout the study. This is explained by the
reduced relative lean mass of DIO-GM, as plasma creatinine levels
correlate positively with muscle mass [47,48]. In addition, increased
creatinine clearance was observed in obese humans [49,50].
By feeding the same diet to both L-GM and DIO-GM, metabolic
consequences of obesity in comparison to normal weight can be
evaluated in the absence of confounding effects due to different di-
etary components or distribution of energy sources within the diet.
However, the change to fat as the dominant energy source resulted in
changes (e.g. increase of total plasma cholesterol and bilirubin con-
centrations) in L-GM that have to be taken into account for the
interpretation of data from DIO-GM (Figure 2A, Suppl. Table 3).
Analysis of glucose metabolism in obese (FW 30, mean fat mass
43.8%) and morbidly obese minipigs (FW 54, fat mass 53.8%)
revealed reduced glucose tolerance combined with fasting andepithelia adjacent to an area of fat tissue necrosis (right side). Asterisk marks the
section proﬁle of an endocrine pancreatic islet. Bar ¼ 100 mm. I: Hepatic foam cell
granuloma of lipid-loaded macrophages. Inset to I: Positive fat staining (oil-red, fat
stains orange-red) in a cryo-section of liver tissue. Bars ¼ 100 mm. J: Myocardial
interstitial lipomatosis. Asterisk: Myocardial Purkinje-cells. Bars ¼ 100 mm. KeL:
Pulmonary lymphangiectasia and lipidosis. Bar ¼ 100 mm. L: Positive fat-staining (oil-
red, fat stains orange-red) in a cryo-section of lung tissue. Inset to L: Immunohisto-
chemical detection (brown color) of LYVE1 (lymphatic marker). Asterisk: Blood capillary.
Parafﬁn section. Chromogene: DAB. Nuclear counterstain: Hemalaun. Bar ¼ 25 mm.
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Brief Communicationstimulated hyperinsulinemia and increased HOMA-IR, indicative of an
insulin-resistant state. Insulin sensitivity and glucose tolerance dete-
riorated with increasing obesity as indicated by increased AUC glucose,
AUC insulin, and HOMA-IR despite of a lower glucose load during IVGTT
(60% of glucose in FW 54 compared to FW 30). The association of
insulin resistance and obesity is a well-known feature in humans [51].
Reduced glucose tolerance despite substantial hyperinsulinemia sug-
gests some degree of decompensation as insulin secretion does not
fully match the demand. Future clamp studies [52] using glucose
tracers and evaluation of insulin clearance [53], an important additional
modulator of plasma insulin concentration, will be used to characterize
further glucose control in DIO-GM. Due to their size and blood volume,
good compliance with training and the possibility of central arterial or
venous catheter placement large animal models like pigs are more
suitable for such studies [20].
Resting heart rate and heart rate during activity was found distinctly
elevated in DIO-GM. Elevated resting heart rate is considered a risk
factor for cardiovascular disease [54,55] and typically correlates with
blood pressure [56]. Negative consequences of chronically increased
heart rate/blood pressure as cardiac hypertrophy [57] were not
observed in DIO-GM, however their heart weight was generally
increased compared to L-GM.
The metabolic phenotype of the present DIO-GM model might have
been triggered not only by HFHE-diet feeding and physical inactivity but
also by ovariectomy. The lack of circulating estrogens is associated
with increased food intake, reduced energy expenditure, increased
body weight, and adiposity as well as altered body fat distribution and
insulin resistance in animals and humans [58e61].
To validate this DIO-GM model for drug candidate testing, morbidly
obese animals were treated with a long-acting GLP1R agonist previously
tested in DIO mice [28]. A four-week treatment period distinctly reduced
food intake and BW in ad libitum-fed DIO-GM. Positive effects on food
intake and BW reduction were achieved using a much lower dose (up to
0.2 mg/kg BW ¼ 0.02 mg per day) compared with the human dose of
liraglutide (up to 3 mg per day) for obesity [33]. Similar to trials in
humans, gastrointestinal adverse effects like nausea were present at the
start but resolved within the ﬁrst days of treatment. These data suggest
similar positive effects of the GLP1R agonist in obese humans and pigs,
although pigs seem to bemore sensitive towards this class of drugs [62].
Long-term treatment trials can determine the peptide’s full potency and
efﬁcacy on body weight gain, and metabolic parameters. Since pigs lack
uncoupling protein 1 (UCP1) [63], evaluation of the GLP1R agonist’s
effect on uncoupled respiration/thermogenesis as has been described in
mice and rats [64] may be more reﬂective of the human state where
UCP1 levels are relatively low compared to mice [21].
A prominent ﬁnding in DIO-GM was multifocal, large-scale visceral adi-
pose tissue inﬂammation and adipocyte necrosis, which was not previ-
ously described in this species. By contrast, subcutaneous adipose tissue
was not affected. Obesity-associated adipose tissue inﬂammation has
been described in rodents [65] and humans [17,66]. Despite a detailed
knowledge of obesity-associated metabolic consequences, triggers and
underlying mechanisms of adipose tissue inﬂammation as well as their
causal relationships to comorbidities are uncertain [18]. Generally,
extrinsic or intrinsic factors are potential triggers whereby intrinsic factors
can originate from living or dying/dead adipocytes. Bacterial-derived li-
popolysaccharides [67] entering the circulation due to increased obesity-
associated gut-permeability [68], increased FFA concentrations [69,70]
and the lack of estrogens [71] were linked to adipose tissue inﬂamma-
tion. Also, relative deﬁciency in vitamin E, a potent scavenger of reactive
oxygen species (ROS), favoring (per)oxidative alteration of lipids and cell
membranes with formation of free radicals has been discussed as trigger188 MOLECULAR METABOLISM 16 (2018) 180e190  2018 The Authors. Published by Elsevier GmbH.for fat tissue inﬂammation [72]. Furthermore, the interstitial release of
active pancreatic lipolytic and proteolytic enzymes [73] might contribute
to inﬂammation and necrosis as well as hypoxia due to vascular damage,
compression, insufﬁcient angiogenesis [74] or mechanical stress
resulting in incorrect remodeling of WAT extracellular matrix (ECM) and
impaired expansion of adipocytes [75,76].
The reason for exclusive observation of adipose tissue inﬂammation and
necrosis in visceral adipose tissue depots of DIO-GM is currently un-
known but indicates a generally increased susceptibility of severely hy-
pertrophic retroperitoneal adipocytes to undergo necrosis possibly due to
differences in compensatory mechanisms for increasing obesity, e.g. fat
composition, remodeling processes, or vascularization.
For the evaluation of the pathogenic relevance of potential triggers of
adipose tissue inﬂammation, underlying mechanisms and the multi-
organic consequences of morbid obesity a biobank of selected tis-
sues and body ﬂuids from lean and obese minipigs was established.
The focus was set on sampling of altered and unaltered adipose tissue
from a large range of fat depots (subcutaneous: back, abdomen;
visceral: abdominal subperitoneal, perirenal, mesenteric, omental). In
this way, a unique resource was generated from adult minipigs that
had undergone a serial metabolic characterization within an obser-
vation period of 70 weeks.
In conclusion, Munich DIO minipigs present the hallmarks of the
metabolic syndrome with extensive adipose tissue inﬂammation. They
constitute a valuable model for the evaluation of upstream triggers,
underlying mechanisms and metabolic consequences of adipose tis-
sue inﬂammation. They can serve as a valuable model for testing of
novel drug candidates.
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